Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia

Nilotinib is a tyrosine kinase inhibitor used to treat patients with chronic myeloid leukemia (CML). This agent is also being studied in neurodegenerative disorders including Parkinson disease. Studies have shown that nilotinib may decrease the accumulation of parkin substrates and decrease the loss...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Justine, Shah, Paarth, Moguel-Cobos, Guillermo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875312/
https://www.ncbi.nlm.nih.gov/pubmed/31781436
http://dx.doi.org/10.1155/2019/3679319

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875312/
https://www.ncbi.nlm.nih.gov/pubmed/31781436
http://dx.doi.org/10.1155/2019/3679319

Ejemplares similares